IO Biotech reports $8.4 mln Q3 net loss

IO Biotech

14/11/2025 13:13

Overview

IO Biotech reports Q3 net loss of $8.4 mln, operating expenses decreased yr/yr

Company narrowly missed statistical significance in Phase 3 trial for advanced melanoma

Meeting with FDA scheduled to discuss new Phase 3 trial design for advanced melanoma

Outlook

Company expects cash reserves to support operations through Q1 2026

Meeting with FDA scheduled to discuss new Phase 3 trial design for advanced melanoma

Result Drivers

Research and development expenses were $13.7 million for the three months ended September 30, 2025, compared to $20.2 million for the three months ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$8.38 mln
Q3 Basic EPS
-$0.13
Q3 Operating Expenses
$19.36 mln
Q3 Operating Income
-$19.36 mln
Q3 Pretax Profit
-$10.04 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for IO Biotech Inc is $3.00, about 72.9% above its November 13 closing price of $0.81

Press Release: ID:nGNX5jGM31

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)